ALZHEON
Alzheon is a clinical-stage biotechnology company focused on womanchild brain health, memory, and aging, developing transformative treatments for Alzheimer’s disease and other neurodegenerative disorders. They are building a pipeline of innovative drugs to improve the lives of patients by preventing the cognitive and functional decline associated with neurodegeneration. They have a distinct ability to make success advances in the challenging field of therapeutics for Alzheimer’s and other neurodegenerative disorders.
ALZHEON
Industry:
Biotechnology Clinical Trials Health Care Therapeutics
Founded:
2013-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.alzheon.com
Total Employee:
11+
Status:
Active
Contact:
+1 857 214-7242
Total Funding:
136.45 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
ImaginAb
ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
Current Advisors List
Board_member
Board_member
2012-01-01
Current Employees Featured
Ken Mace Chief Financial Officer @ Alzheon
Chief Financial Officer
2021-01-01
Martin Tolar Founder, President & CEO @ Alzheon
Founder, President & CEO
2013-01-01
John Hey Chief Scientific Officer @ Alzheon
Chief Scientific Officer
Adem Albayrak Head of Operations @ Alzheon
Head of Operations
2021-01-01
Patrick Kesslak VP Clinical Development & Medical Affairs @ Alzheon
VP Clinical Development & Medical Affairs
2022-04-01
Susan Flint Vice President of Clinical Operations @ Alzheon
Vice President of Clinical Operations
2022-04-01
Erwan de Naurois VP of Finance @ Alzheon
VP of Finance
2022-04-01
Founder
Investors List
National Institute on Aging
National Institute on Aging investment in Grant - Alzheon
Ally Bridge Group
Ally Bridge Group investment in Series B - Alzheon
Scott H. Cohen
Scott H. Cohen investment in Series A - Alzheon
Ally Bridge Group
Ally Bridge Group investment in Series A - Alzheon
Key Employee Changes
Official Site Inspections
http://www.alzheon.com Semrush global rank: 2.92 M Semrush visits lastest month: 5.58 K
- Host name: 61.171.211.130.bc.googleusercontent.com
- IP address: 130.211.171.61
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Alzheon"
Alzheon - Wikipedia
Alzheon was founded in July 2013 by Martin Tolar, MD, PhD, a veteran of Alzheimer's drug programs, [2] who serves as president and CEO of the organization. [3] Alzheon completed a …See details»
Alzheon Management Team - Alzheon | Preserving …
Management Team Dr. Tolar serves as the Founder, President & CEO of Alzheon. Prior to founding Alzheon in June 2013, Dr. Tolar held executive positions in several life sciences companies, where he has successfully …See details»
Alzheon - Crunchbase Company Profile & Funding
Alzheon is a clinical-stage biotechnology company focused on womanchild brain health, memory, and aging, developing transformative treatments for …See details»
Alzheon, Inc. | Preserving Future Memories | LinkedIn
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.See details»
Alzheon - Org Chart, Teams, Culture & Jobs - The Org
View Alzheon's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Alzheon 2025 Company Profile: Valuation, Funding
When was Alzheon founded? Alzheon was founded in 2013. Where is Alzheon headquartered? Alzheon is headquartered in Framingham, MA. What is the size of Alzheon? Alzheon has 31 total employees. What industry is Alzheon in? …See details»
Org Chart Alzheon - The Official Board
Organizational Chart of Alzheon. Alzheon www.alzheon.com. has 19 executives +1 508 861 7709; Add an executive. Alzheon (ALZH) News . Anything missing? We search for you. Print or …See details»
Alzheon Board of Directors - Alzheon | Preserving …
Board of Directors Executive Chairman of Cantex Pharmaceuticals, Inc. Former Vice Chairman and President of IVAX Corporation Mr. Flanzraich brings to Alzheon more than 30 years of executiveSee details»
Alzheon - Funding, Financials, Valuation & Investors - Crunchbase
Alzheon is funded by 4 investors. Alerce Medical Technology Partners and National Institute on Aging are the most recent investors. Alzheon has a post-money valuation in the range of $50M …See details»
Alzheon CEO and Key Executive Team | Craft.co
Alzheon's Founder, President, CEO and Director is Martin Tolar. Other executives include Neil Flanzraich, Executive Chairman of the Board of Directors; Susan Abushakra, Chief Medical …See details»
Alzheon, Inc. Company Profile | Framingham, MA | Competitors ...
Find company research, competitor information, contact details & financial data for Alzheon, Inc. of Framingham, MA. Get the latest business insights from Dun & Bradstreet.See details»
Alzheon Company Profile - Office Locations, Competitors ... - Craft
Alzheon is a biotechnology company focused on womanchild brain health, memory and aging, developing transformative treatments for Alzheimer’s disease and other neurodegenerative …See details»
Alzheon - Contacts, Employees, Board Members, Advisors & Alumni
Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders. New. ... Experience the new Crunchbase, powered by AI . Experience the new …See details»
Alzheon - VentureRadar
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical …See details»
Alzheon raises $10m to advance oral Alzheimer's candidate
2 days ago Armed with preliminary clinical data, US start-up Alzheon has raised $10 million to help take its oral Alzheimer's therapy ALZ-801 into a phase II/III trial. The financing means that …See details»
Our Vision | Innovative Drug Development - Alzheon
Our vision at Alzheon We strive to change the standard of care. Passion We are passionately dedicated to developing effective treatments for Alzheimer’s disease and other devastating …See details»
Alzheon Raises $100 Million Series E Financing Round to Advance ...
Jun 12, 2024 Alzheon previously raised $50 million through a Series D financing round in 2022. FRAMINGHAM, Mass., June 12, 2024--Alzheon, Inc., a clinical-stage biopharmaceutical …See details»
Alzheon: Advancing Alzheimer's Treatment with Innovative Therapies
Apr 28, 2023 Alzheon Success Story. Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations.The content in this post has been …See details»
Framingham biopharma company raises $100M for Alzheimer’s …
Jun 12, 2024 Alzheon, a Framingham-based biopharmaceutical company, has raised $100 million in Series E financing to advance development and the commercial launch of an oral …See details»
Alzheimer's Drug Developer Alzheon Closes $100M Series E …
Jun 12, 2024 Alzheon completed an oversubscribed $50 million Series D financing in 2022, with the capital raised from undisclosed investors. The company won a $10 million Series A round …See details»